Nymox Pharmaceutical Corp. (Nasdaq: NYMX) announced successful new study results from a long-term Phase 3 trial of the prostate cancer treatment fexapotide sending the stock price soaring $2.02 to close at $4.45.
Nymox Pharmaceutical reports positive study results
August 24, 2016 at 19:25 PM EDT